Acurox Panel Review Complicated By FDA's Uncertainty Over How Much Evidence Is Needed To Prove Abuse Deterrence
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is not convinced that additives meant to make the immediate-release oxycodone formulation difficult to ingest, snort or inject will have their intended deterrent effect.